Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer vaccine
Biotech
IO lays off 50% after FDA derails cancer vaccine approval plan
IO Biotech has resorted to halving its workforce after the FDA knocked back its plans to seek approval for its cancer vaccine.
James Waldron
Sep 29, 2025 8:55am
Nykode bets future on cancer trial after losing Genentech pact
Aug 27, 2025 8:25am
PDS reports 39 months OS in phase 2 head and neck cancer trial
Aug 25, 2025 9:00am
Cancer vaccine's 'narrow' fail won't stop IO heading to FDA
Aug 11, 2025 9:48am
Scancell picks winner from phase 2 cancer vaccine face-off
Jul 22, 2025 9:38am
BioNTech's chief strategy officer heads for the exit
Jul 17, 2025 10:55am
